NICHOLAS AUSTIN: Open Payments
NPI 1063069383 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,732 in 86 payments from 25 companies in 2025. Trend: 2023 $985 · 2024 $1,692 · 2025 $1,732
Food & beverage: $1,711Education: $21
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $222 |
| Amgen Inc. | 11 | $210 |
| Novartis Pharmaceuticals Corporation | 7 | $194 |
| GlaxoSmithKline, LLC. | 10 | $153 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $98 |
| Corcept Therapeutics | 4 | $94 |
| PFIZER INC. | 4 | $88 |
| ABBVIE INC. | 4 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
Products named: LEQVIO, EVENITY, TRELEGY ELLIPTA, AIRSUPRA, XIFAXAN, Kerendia, Korlym, REXULTI.
Industry payments across WA — which companies pay providers there.
